RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
31 hedge funds and large institutions have $18.7M invested in RVL Pharmaceuticals plc Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 12 closing their positions.
57% more capital invested
Capital invested by funds: $11.9M → $18.7M (+$6.8M)
11% less funds holding
Funds holding: 35 → 31 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Athyrium Capital Management
New York
|
+$13.2M |
| 2 |
RA
Rovida Advisors
Fort Lauderdale,
Florida
|
+$3.95M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.83M |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.62M |
| 5 |
Renaissance Technologies
New York
|
+$712K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$136K |
| 2 |
E
Ergoteles
New York
|
-$122K |
| 3 |
Morgan Stanley
New York
|
-$92.1K |
| 4 |
Goldman Sachs
New York
|
-$80K |
| 5 |
HF
HRT Financial
New York
|
-$67K |
RVLP Hedge Fund Activity: Q4 2021 in Review
31 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2021, worth a combined $18.7M — up 57% from $11.9M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RVLP and 8 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Athyrium Capital Management, opening a new position worth an estimated $13.2M. The largest seller was Millennium Management, cutting an estimated $136K.
- 31 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2021, down from 35 in Q3 2021.
- Funds reported $18.7M of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2021, up 57% quarter-over-quarter.
- 8 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2021 and 12 closed out, a net change of -4 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2021 was Athyrium Capital Management, an estimated $13.2M added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2021 was Millennium Management, an estimated $136K sold.
Based on aggregated 13F filings for Q4 2021.